Search
Brexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalThe development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066]. … brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare
Acenocoumarol
go.drugbank.com/drugs/DB01418ApprovedInvestigationalThis prevents carboxylation of vitamin K-dependent clotting factors, II, VII, IX and X, and interferes with coagulation.
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnEstradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. … As a pro-drug of estradiol, estradiol benzoate therefore has the same downstream effects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located
Cytochrome b-c1 complex subunit 1, mitochondrial
go.drugbank.com/bio_entities/BE0001005TargetHumansThe respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.
Polypeptides: Cytochrome b-c1 complex subunit 1, mitochondrialSynonyms: Ubiquinol-cytochrome-c reductase complex core protein 1, Core protein IHolliday junction branch migration complex subunit RuvB
go.drugbank.com/bio_entities/BE0002792TargetThermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)The RuvA-RuvB-RuvC complex processes Holliday junction (HJ) DNA during genetic recombination and DNA repair, while the RuvA-RuvB complex plays an important role in the rescue of blocked DNA replication … The RuvB hexamer acts as an ATP-dependent pump, pulling dsDNA into and through the RuvAB complex.
Polypeptides: Holliday junction branch migration complex subunit RuvBCytochrome b-c1 complex subunit 2, mitochondrial
go.drugbank.com/bio_entities/BE0003855TargetHumansThe respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.
Polypeptides: Cytochrome b-c1 complex subunit 2, mitochondrialSynonyms: Ubiquinol-cytochrome-c reductase complex core protein 2, Core protein IICytochrome b-c1 complex subunit 6, mitochondrial
go.drugbank.com/bio_entities/BE0003856TargetHumansThe respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase … Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation.
Polypeptides: Cytochrome b-c1 complex subunit 6, mitochondrialSynonyms: Complex III subunit 6, Complex III subunit VIIIInner membrane complex sub-compartment protein 3
go.drugbank.com/bio_entities/BE0009269TargetPlasmodium falciparum (isolate 3D7)Polypeptides: Inner membrane complex sub-compartment protein 3Valsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigationalValsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the pro...
Mixtures: VALSACOR COMP 160/25MG, VALSACOR COMP 160/25MGProducts: VALSARTAN EG, VALSARTAN TABLETAS RECUBIERTAS X 40 MGCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression